1.
Bioorg Med Chem Lett
; 14(9): 2265-8, 2004 May 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15081022
RESUMO
A series of novel compounds with both 5-lipoxygenase (5-LO) inhibitory and histamine H(1) receptor antagonist activity were designed for the treatment of asthma. These dual-function compounds were made by connecting 5-LO and H(1) pharmacophores,N-hydroxyureas and benzhydryl piperazines, respectively. A range of in vitro activities was observed, with the furan analog 10 demonstrating both activities in an animal model. The activities observed were compared to single-function drugs.